검색어: cells (몰타어 - 영어)

prekawzjonijiet speċjali fil-marda tas-sickle cells
special precautions in sickle cell disease

medja ta’ cd4 (cells/ml) (sensiela)
median cd4 (cells/ml) (range)

l-idroġenu u ċelluli ta' kombustjoni (fuel cells)
hydrogen and fuel cells

it-tumuri tal-mast cell huma proliferazzjonijiet kanċerużi tal-mast cells.
mast cell tumours are cancerous proliferations of mast cells.

it- t- cells iridu jiġu ‘ attivati ’ qabel ma jaħdmu.
t-cells must be ‘ activated ’ before they work.

prekawzjonijiet speċjali fis-sickle cell trait u l-marda tas-sickle cells
special precautions in sickle cell trait and sickle cell disease

irkupru sħiħ tat-t-helper cells u limfoċiti b dam biex iseħħ madwar sentejn.
a complete recovery of t-helper cells and b-lymphocytes is delayed for up to 2 years.

talimogene laherparepvec hu prodott f’ċelloli vero cells b’teknoloġija rikombinanti tad-dna.
talimogene laherparepvec is produced in vero cells by recombinant dna technology.

stabbilixxi t-titru fuq sospensjoni ta' 106 cells għal kull ml minn grupp omoloġeju tar-ralstonia solanacearum.
determine the titre on a suspension of 106 cells per ml from the homologeous strain of ralstonia solanacearum.

l-ewwel ringiela ta' hair cells ta' barra għandha iktar ħsara serja mit-tieni ringiela.
the first row of outer hair cells is more seriously damaged than the second row.

asc-us=Ċelluli skwamużi atipiċi ta’ sinifikanza mhux determinata (atypical squamous cells of undetermined significance).
asc-us=atypical squamous cells of undetermined significance.

it-telf tassmigħ fi frekwenza speċifika għalhekk huwa assoċjat ma' ħsara tal-hair cells f'partijiet speċifiċi tal-cochlea.
hearing loss at a given frequency is therefore associated with hair cell damage in specific parts of the cochlea.

in vitro, f' ċelluli ta' langerhans li nkisbu minn ġilda normali, tacrolimus naqqas l-attività stimulatorja lejn it-t cells.
in vitro, in langerhans cells isolated from normal human skin, tacrolimus reduced the stimulatory activity towards t cells.

0.1% tal-pazjenti li kienu qed jirċievu taltz żviluppaw għadd ta’ newtrofili ta’ <1,000 cells/mm3.
0.1% of patients receiving taltz developed a neutrophil count <1000 cells/mm3.